Advancing CYP2D6 Pharmacogenetics Through a Pharmacoequity Lens.
Sign Up to like & getrecommendations! Published in 2023 at "Clinical pharmacology and therapeutics"
DOI: 10.1002/cpt.2890
Abstract: Over 20% of Food and Drug Administration (FDA)-approved drugs in the United States are metabolized by the hepatic enzyme cytochrome P450 2D6 (CYP2D6). The gene encoding CYP2D6 is highly polymorphic and genetic variation has been… read more here.
Keywords: genetic variation; cyp2d6 genetic; cyp2d6; variation ... See more keywords
Influence of CYP2D6 genetic variation on adverse events with propafenone in the pediatric and young adult population
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Science"
DOI: 10.1111/cts.13296
Abstract: Propafenone is an antiarrhythmic drug metabolized primarily by cytochrome P450 2D6 (CYP2D6). In adults, propafenone adverse events (AEs) are associated with CYP2D6 poor metabolizer status; however, pediatric data are lacking. Subjects were tested for 10… read more here.
Keywords: genetic variation; cyp2d6 genetic; cyp2d6; propafenone ... See more keywords